Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument

Esper, Peg; Mo, Fei; Chodak, Gerald; Sinner, Michael; Cella, David; Pienta, Kenneth J.

doi:10.1016/s0090-4295(97)00459-7

Cited by 696Cancer survivorship and careCancer-related cognitive impairment studiesHealth Systems, Economic Evaluations, Quality of Life

Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument

Esper, Peg, Mo, Fei, Chodak, Gerald, Sinner, Michael, Cella, David, Pienta, Kenneth J.·1997·Urology

DOI 10.1016/s0090-4295(97)00459-7

Open this paper in CoChat — free account

Abstract

Objectives As the incidence of prostate cancer in the United States exceeds 330,000 in 1997, increasingly more men are faced with treatment choices for which there is no clear approach. At every stage of disease, these treatment choices may involve clinically equivalent modalities that differ in side effects and impact upon quality of life (QOL). Comprehensive, yet efficient, questionnaires are needed to measure QOL in patients with prostate cancer.Methods Developed as a disease-specific adjunct to the Functional Assessment of Cancer Therapy (FACT) measurement system, a 12-item prostate cancer subscale (PCS) was developed and tested in three independent samples: a subscale development sample (n = 43), validity sample 1 (n = 34), and validity sample 2 (n = 96). The 12 items ask about symptoms and problems specific to prostate cancer. These questions are added to the general (FACT-G) instrument, thereby comprising a 47-item questionnaire.Results Internal consistency of the PCS ranged from 0.65 to 0.69, with coefficients for FACT-G subscales and aggregated scores ranging from 0.61 to 0.90. Concurrent validity was confirmed by the ability to discriminate patients by disease stage, performance status, and baseline prostate-specific antigen (PSA) level. Sensitivity to change in performance status and PSA score over a 2-month period suggested that some subscales of the FACT-Prostate (P) (including the PCS) are sensitive to meaningful clinical change.Conclusions Our findings support use of the FACT-P as a meaningful component of QOL evaluation in men undergoing therapy for prostate cancer.

Integrity signals

Registry

Crossref · 10.1016/s0090-4295(97)00459-7

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020 · see citing works
Self-citation
Cancer statistics, 1997
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000 · see citing works
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,575 · see citing works
Quality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., Leach, G. E., & Brook, R. H. (1995) · JAMA · doi:10.1001/jama.1995.03520260051032 · Cited by 1,020 · see citing works
Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E. J., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750 · see citing works
Self-citation
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
Tannock, I. F., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L., & Rider, W. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.590 · Cited by 407 · see citing works
Quality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S. (1995) · JAMA · doi:10.1001/jama.273.2.129 · Cited by 281 · see citing works
The association of benign prostatic hyperplasia and cancer of the prostate
Bostwick, D. G., Cooner, W. H., Denis, L., Jones, G. W., Scardino, P. T., & Murphy, G. P. (1992) · Cancer · doi:10.1002/1097-0142(19920701)70:1+ · Cited by 222 · see citing works
Early Detection of Prostate Cancer
Scardino, P. T. (1989) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)01800-0 · Cited by 210 · see citing works
Quality of Life and Functional Status Measures in Patients With Head and Neck Cancer
DʼAntonio, L. L., Zimmerman, G. J., Cella, D. F., & Long, S. A. (1996) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.1996.01890170018005 · Cited by 197 · see citing works
Self-citation
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.
Moore, M. J., Osoba, D., Murphy, K., Tannock, I. F., Armitage, A., Findlay, B., Coppin, C., Neville, A. J., Venner, P. M., & Wilson, J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.689 · Cited by 160 · see citing works
Quality of life and psychosocial status in stage D prostate cancer
Cassileth, B. R., Soloway, M. S., Vogelzang, N. J., Chou, J. M., Schellhammer, P. D., Seidmon, E. J., Kennealey, G. T., & members of the Zoladex Prostate Cancer Study Group (1992) · Quality of Life Research · doi:10.1007/bf00434946 · Cited by 135 · see citing works
Quality of life and treatment of hormone resistant metastatic prostatic cancer
Fosså, S. D., Aaronson, N. K., Newling, D. W. W., Cangh, P. J. V., Denis, L., Kurth, K., & de Pauw, M. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90269-y · Cited by 134 · see citing works
Development and validation of the functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument
Cella, D. F., McCain, N. L., Peterman, A. H., Mo, F., & Wolen, D. (1996) · Quality of Life Research · doi:10.1007/bf00449920 · Cited by 119 · see citing works
Self-citation
Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy
Labrie, F., Bélanger, A., Simard, J., Labrie, C., & Dupont, A. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+ · Cited by 93 · see citing works
The Influence of Stress Management Training In HIV Disease
McCain, N. L., Zeller, J. M., Cella, D. F., Urbanski, P. A., & Novak, R. M. (1996) · Nursing Research · doi:10.1097/00006199-199607000-00009 · Cited by 68 · see citing works
Self-citation
Radiation therapy tolerance limits: For one or for all?-Janeway lecture
Peters, L. J. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960601)77:11 · Cited by 66 · see citing works
Self-citation
Health-related quality of life in patients with advanced prostate cancer: A multinational perspective
Cleary, P. D., Morrissey, G., & Oster, G. (1995) · Quality of Life Research · doi:10.1007/bf02260860 · Cited by 64 · see citing works
Correlates of Stress in HIV Disease
McCain, N. L., & Cella, D. F. (1995) · Western Journal of Nursing Research · doi:10.1177/019394599501700203 · Cited by 55 · see citing works
Self-citation
Palliative care: management of the patient with advanced cancer.
Walsh, D. (1994) · PubMed · Cited by 28 · see citing works
Consensus conference. The management of clinically localized prostate cancer
(1987) · JAMA · doi:10.1001/jama.258.19.2727 · Cited by 16 · see citing works
Untitled work
(1995) · doi:10.1002/1097-0142(19950301)75:5
Self-citation

Flagged first, then by citations

Sorted by citations

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · see citing works
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · see citing works
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · see citing works
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903307 · Cited by 1,564 · see citing works
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer
Wei, J. T., Dunn, R. L., Litwin, M. S., Sandler, H. M., & Sanda, M. G. (2000) · Urology · doi:10.1016/s0090-4295(00)00858-x · Cited by 1,520 · see citing works
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.
(2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-79 · Cited by 1,506 · see citing works
Self-citation
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145 · see citing works
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
Dearnaley, D. P., Sydes, M. R., Graham, J. D., Aird, E. G. A., Bottomley, D., Cowan, R. A., Huddart, R. A., Jose, C. C., Matthews, J. H. L., Millar, J. L., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70143-2 · Cited by 904 · see citing works
The UCLA Prostate Cancer Index
Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., LEAKE, B. D., & Brook, R. H. (1998) · Medical Care · doi:10.1097/00005650-199807000-00007 · Cited by 817 · see citing works
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
Warde, P. R., Mason, M., Ding, K., Kirkbride, P., Brundage, M., Cowan, R. A., Gospodarowicz, M. K., Sanders, K., Kostashuk, E. C., Swanson, G. P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61095-7 · Cited by 579 · see citing works
Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening
Cella, D. F., Hahn, E. A., & Dineen, K. K. (2002) · Quality of Life Research · doi:10.1023/a:1015276414526 · Cited by 523 · see citing works
Self-citation
An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer
van Andel, G., Bottomley, A., Fosså, S. D., Efficace, F., Coens, C., Guerif, S. G., Kynaston, H., Gontero, P., Thalmann, G. N., Akdaş, A., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.030 · Cited by 494 · see citing works
Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument
Ward, W. L., Hahn, E. A., Mo, F., Hernández, L., Tulsky, D. S., & Cella, D. F. (1999) · Quality of Life Research · doi:10.1023/a:1008821826499 · Cited by 470 · see citing works
Self-citation
Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location
Taitt, H. E. (2018) · American Journal of Men s Health · doi:10.1177/1557988318798279 · Cited by 463 · see citing works
Development and Validation of an Abbreviated Version of the Expanded Prostate Cancer Index Composite Instrument for Measuring Health-related Quality of Life Among Prostate Cancer Survivors
Szymanski, K. M., Wei, J. T., Dunn, R. L., & Sanda, M. G. (2010) · Urology · doi:10.1016/j.urology.2010.01.027 · Cited by 457 · see citing works
Comprehensive Comparison of Health-Related Quality of Life After Contemporary Therapies for Localized Prostate Cancer
Wei, J. T., Dunn, R. L., Sandler, H. M., McLaughlin, P. W., Montie, J. E., Litwin, M. S., NYQUIST, L. V., & Sanda, M. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.557 · Cited by 443 · see citing works
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study
Ahmed, H. U., Hindley, R. G., Dickinson, L., Freeman, A., Kirkham, A. P. S., Sahu, M., Scott, R., ALLEN, C. M., van der Meulen, J., & Emberton, M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70121-3 · Cited by 397 · see citing works
Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial
Carducci, M. A., Padley, R. J., Breul, J., Vogelzang, N. J., Zonnenberg, B. A., Daliani, D., Schulman, C. C., Nabulsi, A. A., Humerickhouse, R. A., Weinberg, M. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.176 · Cited by 370 · see citing works
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer
Weinfurt, K. P., Li, Y., Castel, L. D., Fred Saad, C., Timbie, J. W., Glendenning, G. A., & Schulman, K. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi122 · Cited by 358 · see citing works
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01653-2 · Cited by 362 · see citing works
Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials
Reeve, B. B., Mitchell, S. A., Dueck, A. C., Basch, E., Cella, D. F., Reilly, C. M., Minasian, L. M., Denicoff, A. M., O’Mara, A. M., Fisch, M. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju129 · Cited by 350 · see citing works
Self-citation
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Tannock, I. F., Fizazi, K. S., Иванов, С. А., Karlsson, C. T., Fléchon, A., Skoneczna, I. A., Orlandi, F. J., Gravis, G., Matveev, V., Bavbek, S. E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70184-0 · Cited by 288 · see citing works
Main Outcomes of the FRESH START Trial: A Sequentially Tailored, Diet and Exercise Mailed Print Intervention Among Breast and Prostate Cancer Survivors
Demark‐Wahnefried, W., Clipp, E. C., Lipkus, I. M., Lobach, D. F., Snyder, D. C., Sloane, R. J., Peterson, B. L., Macri, J. M., Rock, C. L., McBride, C. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7094 · Cited by 284 · see citing works
Reliability and validity of the functional assessment of cancer therapy-ovarian
Basen-Engquist, K., Bodurka-Bevers, D., Fitzgerald, M. A., Webster, K., Cella, D., Hu, S., & Gershenson, D. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1809 · Cited by 280 · see citing works
Self-citation
Measuring quality of life in chronic illness: The functional assessment of chronic illness therapy measurement system
Cella, D. F., & Nowinski, C. J. (2002) · Archives of Physical Medicine and Rehabilitation · doi:10.1053/apmr.2002.36959 · Cited by 273 · see citing works
Self-citation
Exercise Interventions for Cancer Survivors: A Meta-Analysis of Quality of Life Outcomes
Ferrer, R. A., Huedo-Medina, T. B., Johnson, B. T., Ryan, S. M., & Pescatello, L. S. (2010) · Annals of Behavioral Medicine · doi:10.1007/s12160-010-9225-1 · Cited by 272 · see citing works
Fear of cancer recurrence: a systematic literature review of self‐report measures
Thewes, B., Butow, P., Zachariae, R., Christensen, S., Simard, S., & Gotay, C. (2012) · Psycho-Oncology · doi:10.1002/pon.2070 · Cited by 262 · see citing works
Evaluation of quality of life after laparoscopic surgery: evidence-based guidelines of the European Association for Endoscopic Surgery
Korolija, D., Sauerland, S., Wood-Dauphinée, S., Abbou, C. C., Eypasch, E. P., Caballero, M. G., Lumsden, M. A., Millat, B., Monson, J. R. T., Nilsson, G., et al. (2004) · Surgical Endoscopy · doi:10.1007/s00464-003-9263-x · Cited by 248 · see citing works
Lifestyle Intervention Development Study to Improve Physical Function in Older Adults With Cancer: Outcomes From Project LEAD
Demark‐Wahnefried, W., Clipp, E. C., Morey, M. C., Pieper, C. F., Sloane, R. J., Snyder, D. C., & Cohen, H. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.7224 · Cited by 243 · see citing works
Focal Therapy for Localized Prostate Cancer: A Phase I/II Trial
Ahmed, H. U., Freeman, A., Kirkham, A. P. S., Sahu, M., Scott, R., ALLEN, C. M., van der Meulen, J., & Emberton, M. (2011) · The Journal of Urology · doi:10.1016/j.juro.2010.11.079 · Cited by 233 · see citing works
The Memorial Anxiety Scale for Prostate Cancer: <i>Validation of a new scale to measure anxiety in men with prostate cancer</i>
Roth, A. J., Rosenfeld, B., Kornblith, A. B., Gibson, C., Scher, H. I., Curley‐Smart, T., Holland, J. C., & Breitbart, W. (2003) · Cancer · doi:10.1002/cncr.11386 · Cited by 229 · see citing works
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
Fendler, W. P., Reinhardt, S., Ilhan, H., Delker, A., Böning, G., Gildehaus, F. J., Stief, C. G., Bartenstein, P., Gratzke, C., Lehner, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12240 · Cited by 222 · see citing works
Developing a Valid Patient-Reported Outcome Measure
Rothrock, N. E., Kaiser, K. A., & Cella, D. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.195 · Cited by 222 · see citing works
Self-citation
Living With Prostate Cancer: Patients' and Spouses' Psychosocial Status and Quality of Life
Northouse, L., Mood, D., Montie, J. E., Sandler, H. M., Forman, J. D., Hussain, M., Pienta, K. J., Smith, D. C., Sanda, M. G., & Kershaw, T. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6503 · Cited by 213 · see citing works
Self-citation
Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer
Cella, D. F., Nichol, M. B., Eton, D. T., Nelson, J. B., & Mulani, P. M. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00409.x · Cited by 213 · see citing works
Self-citation
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Kellokumpu‐Lehtinen, P., Harmenberg, U., Joensuu, T. K., McDermott, R., Hervonen, P., Ginman, C., Luukkaa, M., Nyandoto, P., Hemminki, A., Nilsson, S. F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70537-5 · Cited by 212 · see citing works
Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group
Canil, C. M., Moore, M. J., Winquist, E., Baetz, T. D., Pollak, M., Chi, K. N., Berry, S. R., Ernst, D. S., Douglas, L., Brundage, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.129 · Cited by 209 · see citing works
Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
Berthold, D., Pond, G. R., Roessner, M., de Wit, R., Eisenberger, M. A., Tannock, A. I. F., & on behalf of the TAX-327 investigators (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0944 · Cited by 207 · see citing works
Lifestyle Changes for Improving Disease-specific Quality of Life in Sedentary Men on Long-term Androgen-Deprivation Therapy for Advanced Prostate Cancer: A Randomised Controlled Trial
Bourke, L., Gilbert, S. E., Hooper, R., Steed, L., Joshi, M., Catto, J. W. F., Saxton, J., & Rosario, D. J. (2013) · European Urology · doi:10.1016/j.eururo.2013.09.040 · Cited by 205 · see citing works
Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study
Ahmed, H. U., Dickinson, L., Charman, S. C., Weir, S., McCartan, N., Hindley, R. G., Freeman, A., Kirkham, A. P. S., Sahu, M., Scott, R., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.030 · Cited by 201 · see citing works
Management of Complications of Prostate Cancer Treatment
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., & Smith, M. R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0002 · Cited by 196 · see citing works
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Loriot, Y., Miller, K., Sternberg, C. N., Fizazi, K. S., Bono, J. S. D., Chowdhury, S., Higano, C. S., Noonberg, S. B., Holmström, S., Mansbach, H. H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70113-0 · Cited by 191 · see citing works
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
Nilsson, S. F., Cislo, P. R., Sartor, O. A., Vogelzang, N. J., Coleman, R. E., O’Sullivan, J. M., Reuning-Scherer, J. D., Shan, M., Zhan, L., & Parker, C. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw065 · Cited by 184 · see citing works
Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report
Uchida, Τ., Sanghvi, N. T., Gardner, T. A., Koch, M. O., Ishii, D., Minei, S., Satoh, T., Hyodo, T., Irie, A., & Baba, S. (2002) · Urology · doi:10.1016/s0090-4295(01)01624-7 · Cited by 183 · see citing works
Health-Related Quality of Life 2 Years After Treatment With Radical Prostatectomy, Prostate Brachytherapy, or External Beam Radiotherapy in Patients With Clinically Localized Prostate Cancer
Ferrer, M., Suárez, J. F., Guedea, F., Fernández, P., Macías, V., Mariño, A., Hervas, A., Herruzo, I., Ortiz, M. J., Villavicencio, H., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.12.024 · Cited by 181 · see citing works
Exercise Prevents Fatigue and Improves Quality of Life in Prostate Cancer Patients Undergoing Radiotherapy
Monga, U., Garber, S. L., Thornby, J. A., Vallbona, C., Kerrigan, A. J., Monga, T. N., & Zimmermann, K. P. (2007) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2007.08.110 · Cited by 179 · see citing works
Health Related Quality of Life in Men With Prostate Cancer
Penson, D. F., Litwin, M. S., & Aaronson, N. K. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000061964.49961.55 · Cited by 176 · see citing works
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
Chi, K. N., Protheroe, A. S., Rodríguez-Antolín, A., Facchini, G., Suttmann, H., Matsubara, N., Ye, Z., Keam, B., Damião, R., Li, T. M. W. Y., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30911-7 · Cited by 171 · see citing works
Lifestyle Intervention in Men with Advanced Prostate Cancer Receiving Androgen Suppression Therapy: A Feasibility Study
Bourke, L., Doll, H., Crank, H., Daley, A., Rosario, D. J., & Saxton, J. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-1143 · Cited by 163 · see citing works
Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate Cancer
Smith, D. C., Esper, P., Strawderman, M. S., Redman, B. G., & Pienta, K. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1664 · Cited by 158 · see citing works
Self-citation
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Wilkins, A. C., Mossop, H., Syndikus, I., Khoo, V. S., Bloomfield, D. J., Parker, C. C., Logue, J. P., Scrase, C. D., Patterson, H., Birtle, A. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00280-6 · Cited by 149 · see citing works
Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial
Moinpour, C. M., Lovato, L. C., Yee, M., Blumenstein, B. A., Savage, M. J., Troxel, A. B., Eisenberger, M. A., Veith, R. W., Higgins, B., Skeel, R. T., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.20.1537 · Cited by 148 · see citing works
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
DePuy, V., Anstrom, K. J., Castel, L. D., Schulman, K. A., Weinfurt, K. P., & Fred Saad, C. (2007) · Supportive Care in Cancer · doi:10.1007/s00520-006-0203-x · Cited by 145 · see citing works
Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project
Muller, B. G., van den Bos, W., Brausi, M. A., Fütterer, J. J., Ghai, S., Pinto, P. A., Popeneciu, I. V., de Reijke, T. M., Robertson, C. N., de la Rosette, J. J. M. C. H., et al. (2015) · World Journal of Urology · doi:10.1007/s00345-014-1475-2 · Cited by 140 · see citing works
Assessing Anxiety in Men With Prostate Cancer: Further Data on the Reliability and Validity of the Memorial Anxiety Scale for Prostate Cancer (MAX–PC)
Roth, A. J. L., Nelson, C. J., Rosenfeld, B. D., Warshowski, A., O'Shea, N., Scher, H. I., Holland, J. C., Slovin, S. F., Curley, T., Reynolds, T. R., et al. (2006) · Psychosomatics · doi:10.1176/appi.psy.47.4.340 · Cited by 139 · see citing works
Measuring Patientsʼ Perceptions of the Outcomes of Treatment for Early Prostate Cancer
Clark, J. A., Bokhour, B. G., Inui, T. S., Silliman, R. A., & Talcott, J. A. (2003) · Medical Care · doi:10.1097/00005650-200308000-00006 · Cited by 137 · see citing works
A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy
Lee, W. R., Hall, M. C., McQuellon, R. P., Case, L. D., & McCullough, D. L. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01707-2 · Cited by 135 · see citing works
Health-Related Quality of Life, Psychological Distress, and Sexual Changes Following Prostate Cancer: A Comparison of Gay and Bisexual Men with Heterosexual Men
Ussher, J. M., Perz, J., Kellett, A., Chambers, S. K., Latini, D. M., Davis, I. D., Rose, D., Dowsett, G. W., & Williams, S. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2015.12.026 · Cited by 133 · see citing works
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
Fred Saad, C., Cella, D. F., Basch, E., Hadaschik, B. A., Mainwaring, P. N., Oudard, S. M., Graff, J. N., McQuarrie, K., Li, S., Hudgens, S. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30456-x · Cited by 130 · see citing works
Self-citation
RECOVERY OF HEALTH RELATED QUALITY OF LIFE IN THE YEAR AFTER RADICAL PROSTATECTOMY: EARLY EXPERIENCE
Litwin, M. S., McGuigan, K. A., Shpall, A. I., & Dhanani, N. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)61938-4 · Cited by 130 · see citing works
How Does Active Surveillance for Prostate Cancer Affect Quality of Life? A Systematic Review
Bellardita, L., Valdagni, R., van den Bergh, R. C. N., Randsdorp, H., Repetto, C., Venderbos, L. D. F., Lane, J. A., & Korfage, I. J. (2014) · European Urology · doi:10.1016/j.eururo.2014.10.028 · Cited by 128 · see citing works
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00158-4 · Cited by 125 · see citing works
The Association Between Erectile Dysfunction and Depressive Symptoms in Men Treated for Prostate Cancer
Nelson, C. J., Mulhall, J. P., & Roth, A. J. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02127.x · Cited by 123 · see citing works
The Role of Spirituality in the Relationship Between Religiosity and Depression in Prostate Cancer Patients
Nelson, C., Jacobson, C. M., Weinberger, M. I., Bhaskaran, V., Rosenfeld, B., Breitbart, W., & Roth, A. J. (2009) · Annals of Behavioral Medicine · doi:10.1007/s12160-009-9139-y · Cited by 118 · see citing works
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
Agarwal, N., McQuarrie, K., Bjartell, A. S., Chowdhury, S., Gomes, A. J., Chung, B. H., Özgüroğlu, M., Soto, Á. J., Merseburger, A. S., Uemura, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30620-5 · Cited by 120 · see citing works
Self-citation
Carbon ion radiation therapy for prostate cancer: Results of a prospective phase II study
Ishikawa, H., Tsuji, H., Kamada, T., Yanagi, T., Mizoe, J., Kanai, T., Morita, S., Wakatsuki, M., Shimazaki, J., & Tsujii, H. (2006) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2006.08.015 · Cited by 116 · see citing works
Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial
Dawson, J. K., Dorff, T. B., Todd Schroeder, E., Lane, C. J., Gross, M. E., & Dieli-Conwright, C. M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4306-9 · Cited by 112 · see citing works
Reliability across studies from the functional assessment of cancer therapy-general (FACT-G) and its subscales: a reliability generalization
Victorson, D., Barocas, J., Song, J., & Cella, D. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9398-2 · Cited by 141 · see citing works
Self-citation
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
Berthold, D., Pond, G. R., de Wit, R., Eisenberger, M. A., & Tannock, I. F. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn288 · Cited by 107 · see citing works
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
TOMBAL, B. F., Fred Saad, C., Penson, D. F., Hussain, M., Sternberg, C. N., Morlock, R., Ramaswamy, K., Ivanescu, C., & Attard, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30898-2 · Cited by 107 · see citing works
What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN)
Cella, D. F., Paul, D., Yount, S., Winn, R. J., Chang, C., Banik, D., & Weeks, J. C. (2003) · Cancer Investigation · doi:10.1081/cnv-120022366 · Cited by 107 · see citing works
Self-citation
The Chronology of Distress, Anxiety, and Depression in Older Prostate Cancer Patients
Nelson, C. J., Weinberger, M. I., Balk, E., Holland, J. C., BREITBART, W. S., & Roth, A. J. L. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0059 · Cited by 105 · see citing works
Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial
Chambers, S. K., Occhipinti, S., Foley, E., Clutton, S., Legg, M., Berry, M., Stockler, M. R., Frydenberg, M., Gardiner, R. A., Lepore, S. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.8788 · Cited by 102 · see citing works
Effect of telehealth interventions on quality of life in cancer survivors: A systematic review and meta-analysis of randomized controlled trials
Li, J., Liu, Y., Jiang, J., Peng, X., & Hu, X. (2021) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2021.103970 · Cited by 98 · see citing works
Recommended Patient-Reported Core Set of Symptoms to Measure in Prostate Cancer Treatment Trials
Chen, R. C., Chang, P., Vetter, R. J., Lukka, H., Stokes, W. A., Sanda, M. G., Bruner, D. W., Reeve, B. B., & Sandler, H. M. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju132 · Cited by 97 · see citing works
Prospective Study of Outcomes after Percutaneous Biliary Drainage for Malignant Biliary Obstruction
Robson, P., Heffernan, N., Gönen, M., Thornton, R. H., Brody, L. A., Holmes, R., Brown, K. T., Covey, A. M., Fleischer, D., Getrajdman, G. I., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1045-9 · Cited by 97 · see citing works
Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma
Smith, B. D., & Haffty, B. G. (1999) · Radiation Oncology Investigations · doi:10.1002/(sici)1520-6823(1999)7:3 · Cited by 81 · see citing works
PC‐SPES, a dietary supplement for the treatment of hormone‐refractory prostate cancer
Pfeifer, B. L., Pirani, J. F., Hamann, S. R., & Klippel, K. F. (2000) · British Journal of Urology · doi:10.1046/j.1464-410x.2000.00476.x · Cited by 93 · see citing works
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
Morgans, A. K., Chen, Y., Sweeney, C. J., Jarrard, D. F., Plimack, E. R., Gartrell, B. A., Carducci, M. A., Hussain, M., Garcia, J. A., Cella, D. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3335 · Cited by 92 · see citing works
Self-citation
Health outcomes of sexual and gender minorities after cancer: a systematic review
Pratt‐Chapman, M. L., Alpert, A. B., & Castillo, D. A. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01707-4 · Cited by 93 · see citing works
Late Gastrointestinal Toxicity After Dose-Escalated Conformal Radiotherapy for Early Prostate Cancer: Results From the UK Medical Research Council RT01 Trial (ISRCTN47772397)
Syndikus, I., Morgan, R. C., Sydes, M. R., Graham, J. D., & Dearnaley, D. P. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.05.052 · Cited by 90 · see citing works
Threat of Sexual Disqualification: The Consequences of Erectile Dysfunction and Other Sexual Changes for Gay and Bisexual Men With Prostate Cancer
Ussher, J. M., Perz, J., Rose, D., Dowsett, G. W., Chambers, S. K., Williams, S., Davis, I. D., & Latini, D. M. (2016) · Archives of Sexual Behavior · doi:10.1007/s10508-016-0728-0 · Cited by 89 · see citing works
Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role
Hack, T. F., Pickles, T., Ruether, J. D., Weir, L. M., Bultz, B. D., Mackey, J. R., & Degner, L. F. (2009) · Psycho-Oncology · doi:10.1002/pon.1590 · Cited by 89 · see citing works
MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study
Ehdaie, B., Tempany, C. M., Holland, F., Sjoberg, D. D., Kibel, A. S., Trinh, Q., Durack, J. C., Akın, O., Vickers, A. J., Scardino, P. T., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00251-0 · Cited by 88 · see citing works
Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone
Berry, D. L., Moinpour, C. M., Jiang, C. S., Ankerst, D. P., Petrylak, D. P., Vinson, L. V., Lara, P. N., Jones, S., Taplin, M. E., Burch, P. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8207 · Cited by 88 · see citing works
Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery
Robinson, J. W., Donnelly, B. J., Saliken, J. C., Weber, B., Ernst, S., & Rewcastle, J. C. (2002) · Urology · doi:10.1016/s0090-4295(02)01679-5 · Cited by 88 · see citing works
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
Harland, S. J., Staffurth, J. N., Molina, A., Hao, Y., Gagnon, D. D., Sternberg, C. N., Cella, D. F., Fizazi, K. S., Logothetis, C. J., Kheoh, T. S., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.144 · Cited by 87 · see citing works
Self-citation
Mapping FACT-P and EORTC QLQ-C30 to Patient Health Status Measured by EQ-5D in Metastatic Hormone-Refractory Prostate Cancer Patients
Wu, E. Q., Mulani, P. M., Farrell, M. H., & Sleep, D. J. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00195.x · Cited by 87 · see citing works
Leading the Way in Exercise and Diet (Project LEAD):
Demark‐Wahnefried, W., Morey, M. C., Clipp, E. C., Pieper, C. F., Snyder, D. C., Sloane, R. J., & Cohen, H. J. (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00266-0 · Cited by 86 · see citing works
Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer
Freedland, S. J., Eastham, J. A., & Shore, N. D. (2009) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2009.35 · Cited by 83 · see citing works
Lack of Comprehension of Common Prostate Cancer Terms in an Underserved Population
Kilbridge, K. L., FRASER, G. J., Krahn, M. D., Nelson, E. M., Conaway, M. C., Bashore, R., Wolf, A. M. D., Barry, M. J., Gong, D. A., Nease, R. F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3468 · Cited by 81 · see citing works
Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project
Postema, A. W., de Reijke, T. M., Ukimura, O., van den Bos, W., Azzouzi, A.-R., Barret, É., Baumunk, D., Blana, A., Bossi, A., Brausi, M. A., et al. (2016) · World Journal of Urology · doi:10.1007/s00345-016-1782-x · Cited by 81 · see citing works
Symptomatic and quality‐of‐life outcomes after treatment for clinically localised prostate cancer: a systematic review
Whiting, P. F., Moore, T. H., Jameson, C., Davies, P. A., Rowlands, M., Burke, M., Beynon, R., Savović, J., & Donovan, J. (2016) · British Journal of Urology · doi:10.1111/bju.13499 · Cited by 81 · see citing works
Measuring health-related quality of life in men with prostate cancer: A systematic review of the most used questionnaires and their validity
Hamoen, E. H. J., de Rooij, M., Witjes, J. A., Barentsz, J. O., & Rovers, M. M. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.10.005 · Cited by 81 · see citing works
High levels of medical mistrust are associated with low quality of life among black and white men with prostate cancer
Kinlock, B. L., Parker, L. J., Bowie, J. V., Howard, D. L., Laveist, T. A., & Thorpe, R. J. (2017) · Cancer Control · doi:10.1177/107327481702400112 · Cited by 81 · see citing works
The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397)
Dearnaley, D. P., Sydes, M. R., Langley, R. E., Graham, J. D., Huddart, R. A., Syndikus, I., Matthews, J. H. L., Scrase, C. D., Jose, C. C., Logue, J. P., et al. (2007) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2007.02.014 · Cited by 80 · see citing works
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial
Cella, D., Ivanescu, C., Holmstrom, S., Bui, C. N., Spalding, J., & Fizazi, K. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu510 · Cited by 79 · see citing works
Self-citation
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial
Horgan, A. M., Šeruga, B., Pond, G. R., Alibhai, S. M. H., Amir, E., de Wit, R., Eisenberger, M. A., & Tannock, I. F. (2014) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2013.12.001 · Cited by 79 · see citing works
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer
Heidenreich, A., Rawal, S. K., Szkarlat, K., Bogdanova, N. V., Dirix, L. Y., Stenzl, A., Welslau, M., Wang, G., Dawkins, F. W., de Boer, C. J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds505 · Cited by 79 · see citing works
Assessing longitudinal quality of life in prostate cancer patients and their spouses: a multilevel modeling approach
Song, L., Northouse, L., Braun, T., Zhang, L., Cimprich, B., Ronis, D. L., & Mood, D. (2010) · Quality of Life Research · doi:10.1007/s11136-010-9753-y · Cited by 78 · see citing works

Psychometric properties of Functional Assessment of Cancer Therapy-Prostate (FACT-P) in Chinese patients with prostate cancer
Wong, C. K. H., Choi, E. P. H., Tsu, J. H., Ho, B., Ng, A. T. L., Chin, W., & Yiu, M. K. (2015) · Quality of Life Research · doi:10.1007/s11136-015-0993-8 · Cited by 21 · see citing works
The Functional Assessment of Cancer Therapy-Prostate (FACT-P) Scales in Men with Prostate Cancer: Reliability and Validity of the Korean Version
Hong, J. H., Jeon, S. S., Lee, H. M., Choi, Y. H., Kim, S., & Choi, H. Y. (2006) · Journal of Korean Medical Science · doi:10.3346/jkms.2006.21.2.295 · Cited by 29 · see citing works
Validation of the Brazilian Version of Functional Assessment of Cancer Therapy-Prostate—FACT-P (Version 4) in Prostate Cancer Patients
de Held, P. A., Matheus, W. E., Naccarato, A. M. E. P., Rodrigues, R. C. M., Ferruccio, A. A., & Ferreira, U. (2021) · Journal of Cancer Education · doi:10.1007/s13187-021-02024-z · Cited by 2 · see citing works
Quality of life in prostate cancer patients and controls: psychometric validation of the FACTP-4 in Spanish, and relation to urinary symptoms.
Batista-Miranda, J. E., Sevilla-Cecilia, C., Torrúbia, R., Musquera, M., Huguet-Pérez, J., de León, X. P., Rosales, A., SALVADOR-BAYARRI, J., & Villavicencio, H. (2003) · PubMed · Cited by 9 · see citing works
Comparison of the EORTC QLQ PR25 and the FACT-P for assessing quality of life in patients with prostate cancer – an updated literature review
Chen, D. J., Jomy, J., Ning, T., Cheng, S., Khan, M., Bottomley, A., Cella, D. F., Chung, H., Lee, S. F., Emmenegger, U., et al. (2026) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000786
Self-citation

Authors: Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J.
Affiliations: Rush University Medical Center (US)
Corresponding author: Esper, Peg
ORCID: Cella, David
Pienta, Kenneth J.
Venue: Urology
Publisher: Elsevier BV
Published: 1997-12
Volume: 50
Issue: 6
Pages: 920-928
ISSN: 0090-4295 (ISSN-L)
DOI: 10.1016/s0090-4295(97)00459-7
OpenAlex: W2004909463
Cited by: 696
References: 22
Citations by year: 2026: 18 · 2025: 22 · 2024: 34 · 2023: 25 · 2022: 45 · 2021: 34 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 29 · 2016: 33 · 2015: 30 · 2014: 28 · 2013: 31 · 2012: 27
FWCI: 4.00
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Urology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords: prostate cancer, quality of life, Functional Assessment of Cancer Therapy, questionnaire development, concurrent validity, internal consistency, sensitivity to change, prostate-specific antigen, performance status, disease stage
MeSH terms: Aged, Aged, 80 and over, Chicago, Humans, Male, Michigan, Middle Aged, Prostatic Neoplasms, Quality of Life, Surveys and Questionnaires, Sensitivity and Specificity, Reproducibility of Results

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument

Abstract

Integrity signals

Claims the paper makes

Cites

Cited by

Related

Record

About these checks